Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II silibinin for prevention of respiratory failure progression in onco-hematologic patients with COVID-19
2020-001794-77Phase 2Active
- Sponsor
- Institut Català d'Oncologia Girona
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of silibinin in coronavirus disease 2019 (COVID-19), respiratory failure, hematopoietic malignancies and 1 more, sponsored by Institut Català d'Oncologia Girona. Primary endpoint: Proportion of patients requiring mechanical ventilation. Started Jul 2020; status: active.
02
Drugs
silibinin
03
Conditions
coronavirus disease 2019 (COVID-19)respiratory failurehematopoietic malignanciesNon-hematologic malignancy
Beyond the preview
Go deeper on 2020-001794-77.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001794-77.